T. Rowe Price Associates
TRIL

T. Rowe Price Associates’s Trillium Therapeutics Inc. TRIL Stock Holding History

T. Rowe Price Associates’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-512,407
Closed -$4.14M – 2648
2020
Q2 		$4.14M Buy
+512,407
New +$3.17M ﹤0.01% 1403

Other funds holding TRIL

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

T. Rowe Price Associates's TRIL Position: Q3 2020 in Review

T. Rowe Price Associates sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2020, closing a stake of 512,407 shares — an estimated $4.14M sold.

T. Rowe Price Associates first reported a position in TRIL in Q2 2020 and held it in 1 quarter. The position peaked at $4.14M in Q2 2020. 114 funds tracked by Wall St. Rank hold TRIL as of Q3 2020.

  • T. Rowe Price Associates reported no remaining Trillium Therapeutics Inc. position as of Q3 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 512,407 Trillium Therapeutics Inc. shares in Q3 2020, an estimated $4.14M.
  • T. Rowe Price Associates first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 1 quarter.
  • T. Rowe Price Associates's Trillium Therapeutics Inc. position peaked at $4.14M in Q2 2020.
  • 114 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2020.

Based on T. Rowe Price Associates's 13F filing for Q3 2020, filed 16 Nov 2020.